Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$20.6MCash on Hand
41.6mo Cash Runway
Follow OKYO by emailGet an email when OKYO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OKYO, unsubscribe in one click. Privacy
📣 What OKYO Says Is Next
second half of this year · “OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.”
Company press release, Sep 29, 2026 · SEC filing
in 2026 · “We anticipate topline results from this trial in 2026, with ongoing negotiations for clinical sites.”
Company press release, Jan 30, 2026 · SEC filing
this year · “OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP this year.”
Company press release, Jan 23, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
OKYO Pharma will participate in the 2026 Jefferies Global Healthcare Conference in London from November 16 to 19, 2026, with leadership available for one-on-one investor meetings. Form 6-K · SEC filing · Press release
Nov 5, 2026 ·
Chief Executive Officer Robert J. Dempsey is scheduled to present at the Stifel 2026 Healthcare Conference on November 12, 2026 at 9:20 a.m. ET in New York, with one-on-one investor meetings available during the conference. Form 6-K · SEC filing · Press release
Oct 6, 2026 ·
Clinical trial First patients enrolled in the Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain, with the first site activated by Dr. Melissa Toyos in Nashville, TN. The trial gives 4 drops per day for 12 weeks, with ocular pain on a VAS score as the primary endpoint. Form 6-K · SEC filing · Press release
Sep 29, 2026 ·
OKYO Pharma will present at the Eyecelerator conference on October 8, 2026 in New Orleans, with CEO Robert J. Dempsey presenting on unmet needs in corneal and anterior segment diseases. Form 6-K · SEC filing · Press release
Sep 9, 2026 ·
OKYO will present at the Ophthalmology Futures European Forum on September 10 in London and the 5th Annual ESCRS iNovation Day on September 11 at ExCeL London, as it advances urcosimod through its global Phase 3 NEPTUNE trial for neuropathic corneal pain. Form 6-K · SEC filing · Press release
Sep 8, 2026 ·
Announced participation in a fireside chat at the Cantor Global Healthcare Conference on September 10 at 8:35 AM ET, with the Chief Medical Officer and Chief Development Officer presenting. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2027 · Phase 3 · Upcoming Trial · Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP). Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
OKYO holds $20.6M in cash and short-term investments and burns about $1.5M/quarter from operations,
an estimated runway of 41.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:39 · Moderate
Cash runway 42 months
ATM program on file since Feb 2026 +15
Shelf registration (F-3, Feb 2026) +10
Share count +40% in a year +14
Recent financing filings on SEC EDGAR:
Feb 17, 2026 · Underwritten offering, $20M · 424B5
Share count 52,479,527 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full OKYO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OKYO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.